All News Penumbra, Inc.

Equities

PEN

US70975L1070

Market Closed - Nyse Other stock markets 04:00:02 2024-04-16 pm EDT			5-day change	1st Jan Change
210 ^USD	-0.07%		-5.77%	-16.49%

Apr. 12	Penumbra, Inc. : The underdog in healthcare
Mar. 28	Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Penumbra, Inc. : The underdog in healthcare	Apr. 11
Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024	Apr. 09	PR
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	Mar. 27	MT
Truist Securities Cuts Penumbra's Price Target to $280 From $290, Keeps Buy Rating	Mar. 22	MT
Piper Sandler Adjusts Price Target on Penumbra to $290 From $310, Maintains Overweight Rating	Feb. 26	MT
North American Morning Briefing : Traders Await -2-	Feb. 26	DJ
Deutsche Bank Raises Penumbra Price Target to $288 From $257, Maintains Buy Rating	Feb. 23	MT
Truist Securities Cuts Price Target on Penumbra to $290 From $300, Maintains Buy Rating	Feb. 23	MT
Traders Await Fresh Cues After Nvidia-Fueled Rally as US Equity Futures Inch Higher Pre-Bell	Feb. 23	MT
JPMorgan Downgrades Penumbra to Neutral From Overweight, Cuts Price Target to $250 From $284	Feb. 23	MT
Penumbra Q4 Non-GAAP EPS, Revenue Increase; Shares Fall After-Hours	Feb. 22	MT
Penumbra: Q4 Earnings Snapshot	Feb. 22	AQ
Transcript : Penumbra, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (PEN) PENUMBRA Posts Q4 Revenue $284.7M, vs. Street Est of $286.5M	Feb. 22	MT
Earnings Flash (PEN) PENUMBRA Reports Q4 EPS $0.76, vs. Street Est of $0.70	Feb. 22	MT
Penumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 22	PR
Penumbra, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 22	CI
Penumbra, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 22, 2024	Feb. 01	PR
RBC Raises Price Target on Penumbra to $289 From $280, Keeps Outperform Rating	Jan. 12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Penumbra, Inc. : The underdog in healthcare

April 11, 2024 at 09:39 pm EDT